Targeted RNA
Delivery Through
Polymer-Lipid Hybrid
Targeted RNA
Delivery Through
Polymer-Lipid Hybrid
Next-generation polymer–lipid hybrid nanoparticles engineered for precise, organ-specific RNA delivery, driving safer and more effective therapies
Targeted RNA
Delivery Through
Polymer-Lipid Hybrid
Next-generation polymer–lipid hybrid nanoparticles engineered for precise, organ-specific RNA delivery, driving safer and more effective therapies
The Challenge
The missing link in RNA therapeutics
We already know RNA can transform how we treat disease.
What we don’t yet control is where it goes, how long it lasts, and how it behaves in the body. Until delivery is solved, much of this potential remains out of reach.
Our platform
A platform for targeted RNA delivery
Precision Targeting
Engineered nanocarriers that target specific tissues and cell types with exceptional accuracy and minimal off-target effects.
Precision Targeting
Engineered nanocarriers that target specific tissues and cell types with exceptional accuracy and minimal off-target effects.
Precision Targeting
Engineered nanocarriers that target specific tissues and cell types with exceptional accuracy and minimal off-target effects.
Enhanced Safety
Biocompatible materials designed for optimal safety profiles and controlled biodegradation.
Enhanced Safety
Biocompatible materials designed for optimal safety profiles and controlled biodegradation.
Enhanced Safety
Biocompatible materials designed for optimal safety profiles and controlled biodegradation.
Tunable Surface Chemistry
Adaptable technology for precise nanoparticle surface control and diverse RNA applications.
Tunable Surface Chemistry
Adaptable technology for precise nanoparticle surface control and diverse RNA applications.
Tunable Surface Chemistry
Adaptable technology for precise nanoparticle surface control and diverse RNA applications.
The Technology
Hybrid Nanocarrier Technology
Hybrid Nanocarrier Technology
Hybrid Nanocarrier Technology
Therapeutic Applications
Programs Pipeline
01
Cardiac Regeneration
Expanding horizons for RNA therapy applications across multiple disease areas.
Lead Program
Preclinical (TRL 4)
01
Cardiac Regeneration
Expanding horizons for RNA therapy applications across multiple disease areas.
Lead Program
Preclinical (TRL 4)
01
Cardiac Regeneration
Expanding horizons for RNA therapy applications across multiple disease areas.
Lead Program
Preclinical (TRL 4)
02
Neuromuscular Diseases
Precision RNA delivery to muscle tissue for the treatment of genetic and degenerative neuromuscular disorders.
Research (TRL 3)
02
Neuromuscular Diseases
Precision RNA delivery to muscle tissue for the treatment of genetic and degenerative neuromuscular disorders.
Research (TRL 3)
03
CAR-T therapy
Ex vivo RNA delivery to immune cells, advancing toward in vivo delivery strategies for hematologic cancers treatment.
Early research (TRL 2–3)
03
CAR-T therapy
Ex vivo RNA delivery to immune cells, advancing toward in vivo delivery strategies for hematologic cancers treatment.
Early research (TRL 2–3)
Future Therapeutic Areas
Expanding horizons for RNA therapy applications across multiple disease areas.
Future Therapeutic Areas
Expanding horizons for RNA therapy applications across multiple disease areas.
Who we are
Meet the Team
Led by a multidisciplinary team from Politecnico di Torino, combining expertise in pharmacology, biomedical engineering, and biotechnology.
Letizia Nicoletti, PhD
Chief Executive Officer (CEO)
Oversees operations, including nanoparticle production and quality control, ensuring alignment with preclinical development and TRL advancement. Supports business planning, budgeting, and fundraising, contributing to market analysis and product valorization
Letizia Nicoletti, PhD
Chief Executive Officer (CEO)
Oversees operations, including nanoparticle production and quality control, ensuring alignment with preclinical development and TRL advancement. Supports business planning, budgeting, and fundraising, contributing to market analysis and product valorization
Giovanni Paolo Stola
Chief Operating Officer (COO)
Oversees operations, including nanoparticle production and quality control, ensuring alignment with preclinical development and TRL advancement. Supports business planning, budgeting, and fundraising, contributing to market analysis and product valorization
Giovanni Paolo Stola
Chief Operating Officer (COO)
Oversees operations, including nanoparticle production and quality control, ensuring alignment with preclinical development and TRL advancement. Supports business planning, budgeting, and fundraising, contributing to market analysis and product valorization
Valeria Chiono, PhD
Chief Technology Officer (CTO)
Oversees operations, including nanoparticle production and quality control, ensuring alignment with preclinical development and TRL advancement. Supports business planning, budgeting, and fundraising, contributing to market analysis and product valorization
Valeria Chiono, PhD
Chief Technology Officer (CTO)
Oversees operations, including nanoparticle production and quality control, ensuring alignment with preclinical development and TRL advancement. Supports business planning, budgeting, and fundraising, contributing to market analysis and product valorization
Partner with us to advance
RNA therapeutics
We are actively seeking pharmaceutical and research partners to accelerate the development of our RNA delivery platform and bring innovative therapeutics to patients.
Partner with us to advance RNA therapeutics
We are actively seeking pharmaceutical and research partners to accelerate the development of our RNA delivery platform and bring innovative therapeutics to patients.
Partner with us
to advance
RNA therapeutics
We are actively seeking pharmaceutical and research partners to accelerate the development of our RNA delivery platform and bring innovative therapeutics to patients.